# Mabswitch

Source: https://onco.cc/companies/mabswitch/  
OnCo record `mabswitch` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mabswitch is a Los Angeles-area company making antibodies whose strength of binding can be turned up or down by a second, small molecule after they are given. It is applying the idea to CAR-T cells and antibody-drug conjugates for cancer.

## Summary

MabSwitch, Inc. develops ligand-programmable antibodies designed to give control over their activity after administration, and applies them to switchable-affinity T-cell engagers, antibody-drug conjugates and CAR-T cells, according to its website. In 2026 it received two National Cancer Institute SBIR awards: one for a remote-controlled peptide-centric CAR T-cell therapy for solid tumours, whose abstract names neuroblastoma as an example of a low-mutational-burden cancer, and one for an affinity-tunable antibody-drug conjugate against high-grade serous ovarian cancer. All of its programmes are preclinical.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: MabSwitch, Inc.
- HQ: Van Nuys, CA
- Type: biotech
- Website: https://mabswitch.com/

## Notes

- Company website (home and pipeline pages) and the NIH RePORTER records read on 4 November 2026. No named product candidate is given on the website.

## Sources

- Official website: https://mabswitch.com/
- Pipeline: https://mabswitch.com/products/
- NIH RePORTER: award 1R43CA310118-01: https://reporter.nih.gov/project-details/11313251
- NIH RePORTER: award 1R43CA314526-01: https://reporter.nih.gov/project-details/11405623

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)

---
JSON: https://onco.cc/api/v1/entities/mabswitch.json